Asciminib safety study for young adults with CML in the Gulf region
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at the safety and effects of the drug asciminib in young adults (18 and older) with a type of leukemia called chronic myeloid leukemia (CML). It uses information already collected from patients' medical records to see how well the drug works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
- You must have taken the drug asciminib between May 2023 and May 2026.
- You must give permission for your medical data to be used for this study, or the study must have a waiver from an ethics committee.
- Your medical records must have enough information about your asciminib use and key health outcomes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
This study follows real-world patients who are taking a medicine called asciminib for chronic myeloid leukemia (a blood cancer) after their first treatment didn't work or stopped working. Researchers want to see how well asciminib actually helps patients in everyday practice.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.